GCM
UTHR icon

Graham Capital Management’s United Therapeutics UTHR Stock Holding History

Graham Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-951
Closed -$564K – 1527
2026
Q1 		$564K Buy
+951
New +$474K 0.01% 590
2025
Q2 		– Sell
-1,077
Closed -$332K – 1643
2025
Q1 		$332K Buy
+1,077
New +$369K 0.01% 958
2024
Q2 		– Sell
-4,116
Closed -$946K – 1385
2024
Q1 		$946K Sell
4,116
-580
-12% -$131K 0.02% 442
2023
Q4 		$1.03M Buy
4,696
+2,899
+161% +$668K 0.02% 386
2023
Q3 		$406K Buy
+1,797
New +$414K 0.01% 624
2022
Q4 		– Sell
-6,634
Closed -$1.39M – 1361
2022
Q3 		$1.39M Buy
+6,634
New +$1.48M 0.06% 346

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Graham Capital Management's UTHR Position: Q2 2026 in Review

Graham Capital Management sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 951 shares — an estimated $564K sold.

Graham Capital Management first reported a position in UTHR in Q3 2022 and held it in 6 quarters. The position peaked at $1.39M in Q3 2022. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Graham Capital Management reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 951 United Therapeutics shares in Q2 2026, an estimated $564K.
  • Graham Capital Management first reported a position in United Therapeutics in Q3 2022 and held it in 6 quarters.
  • Graham Capital Management's United Therapeutics position peaked at $1.39M in Q3 2022.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.